Transl Lung Cancer Res: Influence of previous thoracic radiotherapy (RT) on the efficacy of anlotinib in patients with recurrent small cell lung cancer (SCLC)

Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial ALTER 1202 Shows that anlotinib Extends Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed Small Cell Lung Cancer
(SCLC) .

The results of a subgroup analysis of the ALTER 1202 study were recently published in the journal Translational Lung Cancer Research to assess the effect of prior thoracic radiotherapy (RT) on the efficacy of anlotinib in patients with recurrent small cell lung cancer (SCLC)

Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial ALTER 1202 Shows that anlotinib Extends Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed Small Cell Lung Cancer

The study divided patients into two groups: RT group and non-RT group
.

Study endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety

The study divided patients into two groups: RT group and non-RT group

In the ALTER 1202 trial, 68 patients (anlotinib, n=46; placebo, n=22) had previously received RT and 51 patients (anlotinib, n=35; placebo, n=16) had not received RT

In the RT subgroup, median PFS was 5.

In the Cox analysis, adjusted for disease stage and recurrence pattern, the use of anlotinib in both the RT group (HR 0.
13; 95% CI: 0.
06-0.
28) and the non-RT subgroup (HR 0.
16; 95% CI: 0.
07-0.
38) associated with prolonged PFS
.

In the anlotinib arm, RT was associated with progression-free survival (PFS) when adjusted for disease stage and recurrence pattern (HR 0.

In the Cox analysis, adjusted for disease stage and recurrence pattern, the use of anlotinib in both the RT group (HR 0.

In the RT subgroup, median OS was 9.

In the Cox analysis, when adjusted for disease stage and recurrence pattern, use of anlotinib was associated with OS in the RT subgroup (HR 0.
47; 95% CI: 0.
22-0.
98), but not in the non-RT subgroup (HR 0.
54; 95%CI: 0.
22-1.
33)
.

In the anlotinib arm, RT was not significantly associated with OS when adjusted for disease stage and recurrence pattern (HR 0.

In the Cox analysis, when adjusted for disease stage and recurrence pattern, use of anlotinib was associated with OS in the RT subgroup (HR 0.

There was no significant difference in ORR between the two treatments in the RT subgroup (P=0.

Taken together, the study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
.
In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
.

Taken together, the study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
.
In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
.
The study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
.
In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
.
The study demonstrated DCR, PFS, and OS benefits with anlotinib compared with placebo in patients with relapsed SCLC who had previously received thoracic radiotherapy
.
In patients without prior thoracic radiation therapy, DCR and PFS benefited with anlotinib compared with placebo
.

Original source:

Original source:

Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS.
Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.
Transl Lung Cancer Res 2021;10(9):3793-3806.
doi: 10.
21037/tlcr-21-632

Liu Y, Cheng Y, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Qin H, Li X, Hamaji M, Park HS.
Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.
Transl Lung Cancer Res 2021;10(9):3793-3806.
doi: 10.
21037/tlcr-21-632 Leave a comment here